# BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

> **NCT07474961** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Anne Louise Tølbøll Sørensen** · enrollment: 400 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinaemia
- Multiple Myeloma

## Interventions

- **DRUG:** teclistamab OR talquetamab OR elranatamab OR linvoseltamab
- **DRUG:** BTK inhibitors (ibrutinib and zanubrutinib)

## Key facts

- **NCT ID:** NCT07474961
- **Lead sponsor:** Anne Louise Tølbøll Sørensen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-03
- **Primary completion:** 2036-12
- **Final completion:** 2036-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07474961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07474961, "BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07474961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*